Background Prophylaxis of HBV recurrence is critical after liver transplantation in HBV
patients. Despite new prophylactic schemes, most European LT centres persist on a …

The combination of hepatitis B immunoglobulin (HBIG) and nucleos (t) ide analogues [NA
(s)] is considered as the standard of care for prophylaxis against HBV recurrence after liver …

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

Materials and Methods. Data of 195 patients with HCC were retrospectively analyzed and
various clinical and pathological factors for survival and tumor-free survival were examined …

A combination of hepatitis B immunoglobulin (HBIG) and nucleos (t) ide analogues (NUCs)
is currently recommended as prophylaxis against the recurrence of hepatitis B virus (HBV) …

Liver transplantation (LT) is the only effective method of treating end‐stage liver disease,
such as various types of liver failure. China has the largest number of patients with hepatitis …

The characterization of hepatitis B virus (HBV) quasispecies in different compartments in
liver transplant (LT) recipients may be helpful in optimizing prophylaxis regimens. The aims …

A number of hepatotrophic viruses affect organ transplant candidates and recipients. The
most important agents causing acute and chronic hepatitis are hepatitis B virus (HBV), with …

Since the early 1990's, hepatitis B immune globulin (HBIG) has been central to the
prevention of hepatitis B virus (HBV) recurrence after liver transplantation. When used in …

Hepatitis B virus (HBV) recurrence rates of 0‐16% had been reported in patients maintained
on nucleoside analogues (NA) after hepatitis B immunoglobulin (HBIG) discontinuation after …